Standout Papers
- Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non–Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With Erlotinib (2005)
- TRIBUTE: A Phase III Trial of Erlotinib Hydrochloride (OSI-774) Combined With Carboplatin and Paclitaxel Chemotherapy in Advanced Non–Small-Cell Lung Cancer (2005)
Citation Impact
1 by Nobel laureates 23 from Science/Nature 95 standout
Citing Papers
Toward personalized treatment approaches for non-small-cell lung cancer
2021 Standout
Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition
2020 StandoutNature
Works of Pam Klein being referenced
Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non–Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With Erlotinib
2005 Standout
TRIBUTE: A Phase III Trial of Erlotinib Hydrochloride (OSI-774) Combined With Carboplatin and Paclitaxel Chemotherapy in Advanced Non–Small-Cell Lung Cancer
2005 Standout
Author Peers
| Author | Oncology | PRM | Surgery | Molecular Biology | Last Decade | Papers | Cites |
|---|---|---|---|---|---|---|---|
| Pam Klein | 1935 | 2023 | 119 | 719 | 7 | 2.6k | |
| Samiran Bisai | 1 | 3 | 8 | 9 | 51 | 465 | |
| Tom Dayton | 3 | 12 | 130 | ||||
| J. Lelièvre | 1 | 1 | 1 | 73 | 30 | 966 | |
| Scott D. Glazer | 225 | 294 | 42 | 152 | 13 | 1.3k | |
| Natalie Williams | 4 | 16 | 14 | 19 | 734 |
All Works
Loading papers...